Production , purification and preparation of various candidiate vaccines

生物技术实验室正在结束与NICHD和NIAID在开发新型结合疫苗方面的合作，以对抗福氏志贺氏菌、宋氏志贺氏菌、百日咳杆菌、甲型流感嗜血杆菌、百日咳杆菌，以及炭疽杆菌和疟疾传播阻断疫苗的蛋白质疫苗。 该实验室与FDA的科学家合作，正在评估从新开发的MDCK细胞生产流感病毒疫苗的潜力，以及从大肠杆菌K1和脑膜炎双球菌C中提取的多糖的结构。生物技术实验室继续通过使用悬浮细胞培养，专注于流感和轮状病毒，开发新的病毒疫苗生产方法。此外，我们还致力于从悬浮生长的HEK细胞中表达呼吸道合胞病毒(RSV)融合蛋白。目前正在进行适当的构建，并正在进行表达和纯化的初步实验。

The Biotechnology Lab is wrapping its collaboration work with the NICHD and NIAID on the development of new conjugated vaccines against Shigella flexneri, Shigella Sonnie, Bortedella pertussis Haemophilus influenzae type A, Bortedella pertussis, and protein vaccines for Bacillus anthracis and Malaria transmission blocking vaccine. Working together with scientists from the FDA, the laboratory is evaluating the potential production of influenza virus vaccine form the newly developed MDCK cells, and on the structure of the polysaccharide from E. coli K1 and Meningococcal C. The Biotechnology Lab continued to work on the development of new production approaches for viral vaccines by using suspension cell culture, concentrating on influenza and rotavirus. In addition we are working on expressing the respiratory syncytial Virus (RSV) fusion protein from HEK cells growing in suspension in bioreactor. The proper constructs are being made and preliminary experiments on expression and purifications are being conducted.